Objective: Hematopoietic syndrome (HS) is a clinical diagnosis assigned to people who present with Ն1 newonset cytopenias in the setting of acute radiation exposure. The World Health Organization convened a panel of experts to evaluate the evidence and develop recommendations for medical countermeasures for the management of HS in a hypothetical scenario involving the hospitalization of 100 to 200 individuals exposed to radiation. The objective of this consultancy was to develop recommendations for treatment of the HS based upon the quality of evidence. Methods: English-language articles were identified in MEDLINE and PubMed. Reference lists of retrieved articles were distributed to panel members before the meeting and updated during the meeting. Published case series and case reports of individuals with HS, published randomized controlled trials of relevant interventions used to treat nonirradiated individuals, reports of studies in irradiated animals, and prior recommendations of subject matter experts were selected. Studies were extracted using the Grading of Recommendations Assessment Development and Evaluation (GRADE) system. In cases in which data were limited or incomplete, a narrative review of the observations was made. No randomized controlled trials of medical countermeasures have been completed for individuals with radiation-associated HS. The use of GRADE analysis of countermeasures for injury to hematopoietic tissue was restricted by the lack of comparator groups in humans. Reliance on data generated in nonirradiated humans and experimental animals was necessary. Results: Based upon GRADE analysis and narrative review, a strong recommendation was made for the administration of granulocyte colony-stimulating factor or granulocyte macrophage colony-stimulating factor and a weak recommendation was made for the use of erythropoiesis-stimulating agents or hematopoietic stem cell transplantation. Conclusions: Assessment of therapeutic interventions for HS in humans exposed to nontherapeutic radiation is difficult because of the limits of the evidence. (Disaster Med Public Health Preparedness. 2011;5:(doi:10.1001/dmp.2011 
H ematopoietic syndrome (HS) is a clinical diagnosis assigned to individuals who present with Ն1 new-onset cytopenias in the setting of whole-body or significant partial-body acute radiation exposure. The severity of lymphopenia and thrombocytopenia correlate in general with cumulative radiation dose and dose rate. 1 The rate of decline in absolute lymphocyte count correlates closely with dose and dose rate, and has been used as a surrogate marker for whole-body dose. 2, 3 The primary causes of HS are radiation-induced suppression of mitosis in hematopoietic stem/progenitor cells and their progeny, resulting in hypocellularity and aplasia of the bone marrow and apoptosis in lymphocytes and other hematopoietic cells.
Although guidelines have been proposed to aid clinicians in the evaluation, triage, and/or medical management of victims of acute radiation injury, 4 ,5 the level of evidence supporting the current recommendations has not been evaluated. The World Health Organization (WHO) convened a panel of experts in Geneva, Switzerland, from March 16 to 18, 2009 , to develop a har-monized approach to the medical management of acute radiation exposure. Among their considerations was the evidence supporting the clinical management of HS. 6, 7 Using the Grading of Recommendations Assessment Development and Evaluation (GRADE) system for evaluating evidence supporting clinical guidelines, 8 the consultation group weighted the available evidence supporting the use of cytokines, hematopoietic stem cell transplantation, or both in the management of HS.
METHODS
Participants in the consultancy were selected based upon their established expertise in the field. They were asked to consider and respond to a virtual scenario in which 100 to 200 victims required hospitalization. English language references were identified by each consultant before the meeting. All of the references were provided to the WHO and were made available to conferees. At the time of the meeting, additional Englishlanguage articles were identified in MEDLINE and PubMed from inception to the time of the consultancy. Search terms included radiation or radiation toxicity or ionizing radiation and therapy or treatment or cytokines or transplantation or hematopoietic system. Publications included case series, individual case reports of humans who were accidentally exposed to ionizing radiation, randomized control trials and cohort studies of humans who received therapeutic radiation or who may not have been exposed to radiation but who received the indicated treatment, reports of experimental studies in irradiated animals, and prior publications of recommendations of other consensus groups. Reference lists and references were distributed periodically throughout the meeting, as specific topics were raised for discussion.
Questions on the clinical management of HS were framed in the PICO format (patient problem, intervention, comparison, and outcome). 9 To assess the quality of the evidence objectively, drafts of GRADE evidence profiles were prepared, according to WHO recommendations for guideline development. 8 Letter assignments (A, B, C, and D) were made based upon the level of certainty that the magnitudes of benefits and harms of an intervention are known (Table 1 of the accompanying article by the same authors). Ranking the evidence with this tool was discussed and clarified by an expert (H.S.) on the GRADE approach. 10, 11 Criteria included study design, study limitations, consistency rate across studies, directness or generalizability of study results, bias, dose-response gradient, and confounding variables. A single individual (R.N.G.) entered all of the data, and the subsequent findings were reviewed for accuracy by a subgroup of conferees (N.D., Z.C., R.S., J.A., and V.M.) in advance of consideration by the entire consultation group. All of the consultants were asked to make final comments before scoring the strength of each recommendation. A final consensus ranking of recommendations was made by e-mail to all of the conferees.
Strong or weak recommendations for the use of hematopoietic cytokines/growth factors or stem cell transplantation were made based upon the balance between desirable and undesirable consequences of alternative treatment strategies, the quality of the evidence, uncertainty about or variability in values and preferences, and impact on resource utilization. A numerical score was used to gauge the strength of recommendations (see the accompanying article by the same authors). These recommendations included one favoring a practice having a high certainty of substantial net benefit (1a) or a practice having a moderate certainty of moderate net benefit (1b). A recommendation against a practice was made when the practice was believed to have a moderate or high certainty of no net benefit (2a) or to have a moderate or high certainty of a small net benefit (2b).
RESULTS

Rationale for Cytokine Administration
Hematopoietic cytokines such as granulocyte colonystimulating factor (G-CSF) and granulocyte macrophage colonystimulating factor (GM-CSF) have been used since the 1980s to treat radiation-associated cytopenias. 12 Although their use in radiation accident victims has been recommended by 2 expert groups, 4 ,5 the quality of the evidence supporting this recommendation is highly variable.
Clinical trial data supporting the use of cytokine efficacy in the treatment of humans with accidental radiation-induced hematopoietic stem/progenitor cell injury is not robust; additional evidence comes from studies in experimental animals. The administration of G-CSF, GM-CSF, erythropoiesis-stimulating agents (ESAs), and/or thrombopoietin-receptor agonists after exposure to ionizing radiation appears to significantly increase circulating blood counts in humans or nonhuman primates [12] [13] [14] [15] ; however, the lack of a human control group (eg, patients not receiving cytokine treatment) limits interpretation of these results. 16 Spontaneous recovery of blood counts occurred several weeks after the appearance of severe cytopenias in humans with HS, even in the absence of cytokine therapy. 17 In an effort to justify the use and efficacy of cytokines in treating HS, researchers have used animal models. Based on the scientific literature suggesting a beneficial effect in the treatment of HS and the evidence of efficacy of cytokines in chemotherapy, a consensus has emerged that it is not ethically justifiable to conduct a placebo-controlled trial of cytokines in human victims of radiation sickness. In light of this lack of clinical equipoise, the best-available scientific evidence comes (and may continue to come) from animal-based experiments. Survival benefits observed in irradiated rhesus macaques and canines receiving G-CSF, GM-CSF, pegylated G-CSF thrombopoietin 13, 18, 19 support continued use of cytokines in humans exposed to high-dose ionizing radiation.
Analysis of Cytokine Effects Using GRADE
In reviewing the evidence of hematological system injury, we found 5 reported accidents (Goiãnia, Brazil; Tokai-mura, Japan; Henan Province, China; Istanbul, Turkey; and Gilan, Iran), that enabled the establishment of bone marrow failure, First Global Consensus on Management of Acute Radiation Syndrome the documentation of cytokine use, and the demonstration of effect on the hematological system. Table 1 provides a summary of an analysis of the evidence. Table 2 is a complete GRADE analysis of the effects of cytokines on overall survival among individuals with cytopenias after exposure to ionizing radiation. Among these accidents, 18 cases of cytokine use were reported. 12, [20] [21] [22] [23] [24] Eight patients received G-CSF and 10 received GM-CSF (Table 1) .
Among the data reported from the Goiãnia accident, 2 patients experienced spontaneous reversal of leukopenia by 35 days postexposure to 6.2 or 7.1 Gy, and 8 individuals demonstrated persistent leukopenia for 24 to 47 days, and GM-CSF therapy was initiated at this time. Four of the individuals treated with cytokines (radiation doses of 2.5-4.4 Gy) survived and recovered from leukopenias. Four of the treated individuals (doses of 4.0-6.0 Gy received) died of Gram-negative sepsis and/or hemorrhagic complications, 3 of whom experienced minimal increase in their white blood cell count ( Table 2 ). Four of the 6 patients from the Tokaimura accident (1 patient) and the Henan Province accident (3 patients) were evaluable by GRADE, and all of them demonstrated improvement in absolute neutrophil count ( Table 2 ).
In the 5 nuclear accidents, among the patients whose exposure dose was Ͼ5 Gy, 1 of 3 patients treated with cytokines survived. At exposures Ͻ5 Gy, 14 of 15 patients survived. The consultation group interpreted this observational finding as suggesting a possible benefit to myelopoiesis used in patients with exposure doses Ͻ5 Gy, when the only likely organ-critical failure is the hematopoietic system.
In assessing the effectiveness of cytokines, the GRADE analysis was severely restricted by our failure to identify any true control or comparator groups. Descriptive studies like these that do not have an appropriate, contemporaneous comparison group allow assessment of hypotheses for possible associations but not robust assessments of causality. 25 Randomized, appropriately designed, and powered studies are much more useful in studying causality. 25 In this case, a temporal association of cytokine administration followed by myeloid recovery should not be inferred as strong evidence of causality.
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Rationale for Stem Cell Transplantation
Hematopoietic stem/progenitor cells of the bone marrow undergo mitotic death after exposure to ionizing radiation, with a D o (the radiation dose that reduces survival to e −1 or 0.37 of its previous value on the exponential portion of the survival curve) for human marrow colony-forming units granulocyte-macrophage of 1.02 ± 0.05 at a dose rate of 2 Gy/min 27 and for human peripheral blood total colony-forming cells of 1.18 ± 0.24 at a dose rate of †The group of patients not requiring treatment for bone marrow failure includes 2 patients from the Goiãnia accident with dose exposures of 6.2 and 7.0 Gy in whom spontaneous late recovery of bone marrow occurred and hence did not require consideration for cytokine therapy; spontaneous recovery in other cases reported in these studies were among patients who had received absorbed doses of radiation in the range of .6 to 2.9 Gy.
‡Two patients from the Tokai-mura accident with bone marrow failure were managed primarily with hematopoetic stem cell transplants. §Outcome of intervention has great clinical significance (survival vs death) because refractory bone marrow failure is considered to be inevitably lethal.
0.8 Gy/min. 28 This particular in vitro measure of sensitivity to radiation correlates with the appearance of the HS that occurs in individuals whose partial-body or whole-body radiation exposure exceeds approximately 1 Gy. 7, 29 The clinical correlate of this laboratory observation is the significantly diminished capacity of hematopoietic stem/progenitor First Global Consensus on Management of Acute Radiation Syndrome cells to proliferate in vivo after a whole-body dose exceeding 2 to 3 Gy.
Depending on the dose, dose rate, and radiation quality factor, various degrees of pancytopenia develop over several weeks after whole-body or significant partial-body exposure. 4, 6, 30 Hypocellularity and aplasia of the bone marrow may occur at doses Ͼ3 Gy. 4, 6, 30, 31 Factors that may exacerbate the effects of radiation include a patient's age, underlying state of health, and overall nutritional status.
Hematopoietic stem/progenitor cell therapy has been recommended for patients with complete aplasia of the bone marrow, as assessed by bone marrow biopsies taken from 2 noncontiguous sites. 4, 5 Such individuals would be expected to have third-or fourth-degree hematopoietic toxicity (Table 3) .
Analysis of the Effects of Bone Marrow Transplantation Using GRADE
A crude meta-analysis of 3 reported incidents in which bone marrow transplantation was used to treat radiation-induced marrow failure was performed. Table 4 provides a summary of this analysis. Table 5 presents a complete GRADE analysis of the question of the impact of bone marrow transplantation on overall survival among individuals with bone marrow failure after exposure to ionizing radiation. In these reports, [32] [33] [34] [35] some of which 
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predate the use of cytokines, survival appeared not to rely on transplantation, and may have been affected adversely by transplantation.
Stratification of the results from the Chernobyl study 33 suggests that survival is more likely among individuals receiving Ͻ9 Gy and no bone marrow transplant. Nevertheless, the data are too restrictive to allow definitive statistical analysis. Survival in 2 additional patients (one receiving a peripheral blood transplant and the other receiving a cord blood transplant) from the Tokaimura accident was possibly longer than predicted by the estimated whole-body radiation dose. 36 These individuals also received concurrent cytokine therapy, and comparators were not available. Data are insufficient to determine the impact of genetically identical bone marrow transplantation on outcomes.
In summary, the data available from these reports strongly suggest that the effect of hematopoietic stem/progenitor cell transplantation is unproven as initial therapy for HS after irradiation.
RECOMMENDATIONS
The consultation group strongly considered the GRADE evidence profiles for cytokine administration and bone marrow transplantation in developing recommendations for the management of HS. The group also derived recommendations in part from results of these therapies in controlled animal trials. During the deliberation process, guidelines provided by expert consensus groups and by national and international societies also were considered, reviewed, and discussed. G-CSF=granulocyte colony-stimulating factor; GM-CSF=granulocyte macrophage colony-stimulating factor; IAEA=International Atomic Energy Agency. Principal criterion for inclusion: All of the studies were observational reports on the outcomes of the use of a cytokine in established refractory bone marrow failure using either G-CSF or GM-CSF. Additional criteria for exclusion: radiation exposure was in a nontherapeutic setting; reporting of the clinical details of the incident is in the public domain; radiation doses received were established with sufficient accuracy as to reliably attribute bone marrow injury to ionizing radiation exposure; reported cases had no other clinical reason to experience bone marrow injury; treatment did not include the use of complex mixtures of cytokines; outcome was not confounded by bone marrow grafting or the use of stem cells; report contained sufficient clinical information to establish clear evidence of bone marrow injury; and report contained sufficient clinical information to establish clear evidence of consequent effects on bone marrow.
*Patients with minor hematological impairment not requiring treatment. †Patients whose bone marrow recovered spontaneously.
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Although the evidence for cytokine administration from radiation incident reports alone is weak, results are remarkably consistent from controlled animal trials 13, 18, 37, 38 and reports recommending the use of CSF in nonirradiated (eg, chemotherapy treated) patients with malignancy, as recommended by the American Society of Clinical Oncology, 39 by the European Society of Medical Oncology, 40 and by consensus groups. 4, 5, 29 The consistency of the observation that cytokines successfully treat hematological injury in animal models and in humans with hematological deficits of nonradiation origin, together with the relatively limited drug-related toxicity reported for certain cytokines, leads to a strong recommendation that these cytokines should be used in the management of radiation-induced hematotopoietic system injury ( Table 6 ).
Health care providers should consider initiating cytokine therapy for exposures of Ն2 Gy and/or a significant decrease in the absolute lymphocyte count, or when it is anticipated that neutropenia of Ͻ.5ϫ10 9 cells per liter will persist for Ն7 days. It is recommended that cytokine therapy with G-CSF or GM-CSF be initiated within 24 hours of exposure. Pegylated G-CSF may be used as an alternative to G-CSF. Patients should continue to receive treatment until their absolute neutrophil count reaches and maintains a level Ͼ1.0ϫ10
9 cells per liter in the absence of active infection. Those with infection should be treated with cytokines, according to the guidelines published by infectious disease societies, including the Infectious Diseases Society of America. 41 Individuals with prolonged anemia, a significant decline in hemoglobin concentration, or both may be candidates for treatment with erythropoietin. In contrast to the relatively short life span of myeloid cells and platelets (Ͻ10 days), the life span of erythrocytes is approximately 120 days. Experiencing a response to erythropoietin will take weeks rather than days. Consideration should be given to the administration of oral iron supplementation in individuals receiving ESAs. ESAs may be considered in the lowest dosage that induces a sufficiently high hemoglobin level to render blood transfusion unnecessary (ie, 9-10 g/dL), although a higher level of hemoglobin may be reasonably targeted on a case-by-case basis. Strong caveats recommending specific indications for the use of ESAs are incorporated in a "black box" warning by the US Food and Drug Administration (FDA). 42 The initial dose of ESAs should follow the recommendations of the FDA, the the European Medicines Agency, or other relevant regulatory authorities, as provided in the manufacturer's labeling. Dosing is based on a patient's hemoglobin level at the initiation of therapy, his or her target hemoglobin level, the observed rate of increase in hemoglobin level, and individual clinical circumstances. Finding few published reports in humans with nonimmunological thrombocytopenia or exposure to radiation, the consultancy group makes no recommendation regarding the use of secondgeneration thrombopoietic growth factors.
Because patients with severe hematopoietic injury may recover, either spontaneously or after G-CSF treatment alone, ARF-ARDS=adult respiratory distress syndrome/acute respiratory failure; GI=gastrointestinal; GvH=graft-vs-host disease; HLA=human leukocyte antigen. Principal criterion for inclusion: All studies with an observational outcome regarding the use of bone marrow transplantation in irradiated individuals with bone marrow failure. Additional criteria for exclusion: radiation exposure was in a nontherapeutic setting; reporting of the clinical details of the incident is in the public domain; reported cases had no other clinical reason to experience bone marrow injury; report contained sufficient clinical information to establish clear evidence of bone marrow injury; report contained sufficient clinical information to establish clear evidence of consequent survival; and information on the radiation doses received was available.
*Unresolved laboratory testing disparity.
clinicians considering bone marrow transplantation are advised to adopt a wait-and-see approach with careful surveillance. Stem/progenitor cell replacement therapy should not be administered until there is a documented lack of spontaneous recovery and/or lack of response following 2 to 3 weeks of cytokine treatment. Survival outcomes have been poor among patients who have received transplants who also have radiation burns, gastrointestinal syndrome, infection, adult respiratory distress syndrome, and/or renal insufficiency [32] [33] [34] [35] [36] ; therefore, it has been recommended that hematopoietic stem/progenitor cell therapy not be used for patients with aplasia and significant injury to another organ system. 4, 7, 29, 43, 44 With these caveats in mind, the consulting group makes a weak recommendation for the administration of allogeneic hematopoietic stem/progenitor cells from the bone marrow, peripheral blood, or cord blood of patients who are unresponsive to cytokine therapy and in whom there is no significant injury to a nonhemopoietic organ system (Table 6 ).
CONCLUSIONS
The WHO panel of experts used the GRADE tool to extract and analyze data from reports of cytokine administration and/or bone marrow transplantation in individuals with HS after exposure to ionizing radiation. The lack of comparator groups in humans restricts these analyses. Nevertheless, together with results of controlled trials in large animals and clinical trials in nonirradiated humans, these analyses support the strong recommendation for G-CSF or GM-CSF administration and the weak recommendation for ESA or hematopoietic stem cell administration in humans with HS. Administer ESAs when prolonged anemia is present to avoid need for red blood cell infusion Weak (C-1b)
Administer hematopoietic stem cells after failure of 2-3 wk of cytokine treatment to induce recovery from marrow aplasia in absence of nonhematopoietic organ failure Weak (D-1b) ANC = absolute neutrophil count; ESA = erythropoiesis-stimulating agents; G-CSF = granulocyte colony-stimulating factor; GM-CSF = granulocyte macrophage colony-stimulating factor.
Strength of recommendation was determined by assignment of quality of the evidence (A-High, B-Moderate, C-Low or D-Very Low) and strong (1a) or weak (1b) recommendation in favor of the practice.
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